2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals

Parenteral Administration Routes and Physiological Constraints

Parenteral drug administration bypasses the gastrointestinal tract and the body's primary protective epithelial barriers, demanding stringent standards for sterility, pyrogenicity, osmolarity, and particulate matter.

Routes and Anatomical Constraints

• Intravenous (IV): Bolus or continuous infusion directly into the venous circulation. Provides immediate $100%$ systemic bioavailability without an absorption phase. Requires aqueous solutions; specialized O/W emulsions (e.g., propofol, IV lipid emulsions) must maintain droplet sizes $< 0.5\ \mu\text{m}$ to prevent capillary fat embolism.
• Intramuscular (IM): Injected into deep skeletal muscle (deltoid, ventrogluteal, vastus lateralis). Volumes typically limited to $\le 2\text{ mL}$ (deltoid) or $\le 4\text{ to }5\text{ mL}$ (gluteal). Can accommodate aqueous solutions, suspensions, and oily depot formulations (e.g., haloperidol decanoate, medroxyprogesterone acetate).
• Subcutaneous (SC): Injected into the subcutaneous adipose tissue. Maximum injection volume is typically $\le 1.5\text{ mL}$. Avoids muscle tissue; suitable for self-administration of small molecules (heparin) and biologics (insulin, monoclonal antibodies).
• Intrathecal (IT) and Epidural: Injected directly into the subarachnoid cerebrospinal fluid (CSF) space (IT) or outside the dura mater (epidural).
  • CRITICAL MANDATORY REQUIREMENT: Neuraxial preparations must be STRICTLY PRESERVATIVE-FREE. Common preservatives (e.g., benzyl alcohol, parabens, phenol, benzalkonium chloride) cause direct neurotoxicity, irreversible chemical arachnoiditis, paraplegia, and death. Preserved multidose vials must NEVER be administered via the spinal route.
  • Neonatal Warning: Benzyl alcohol in neonates causes fatal "gasping syndrome" (severe metabolic acidosis, CNS depression, gasping respirations, and cardiovascular collapse) due to immature hepatic glycine conjugation.

---

Osmolality, Tonicity, and Osmotic Calculations

Normal human blood serum osmolality ranges from $285\text{ to }295\text{ mOsm/kg}$ (roughly isosmotic with $0.9%$ w/v sodium chloride solution).

Tonicity Effects on Erythrocytes:
  |-- Isotonic Solution (~290 mOsm/L) --> Normal RBC morphology (equilibrium)
  |-- Hypotonic Solution (< 250 mOsm/L) --> Water enters RBCs --> Swelling & LYSIS (Hemolysis)
  |-- Hypertonic Solution (> 350 mOsm/L) --> Water exits RBCs --> Shrinkage (CRENATION)

Osmolarity and Route Selection

• Peripheral IV Lines: Solutions with osmolarity between $250\text{ and }900\text{ mOsm/L}$ can generally be infused peripherally.
• Central Venous Lines: Solutions exceeding $> 900\text{ mOsm/L}$ (e.g., total parenteral nutrition [TPN], $3%$ or $5%$ hypertonic NaCl, $\ge 20%$ Dextrose) must be infused via a central venous catheter into the superior vena cava, where high-volume blood flow ($2-3\text{ L/min}$) rapidly dilutes the hypertonic fluid to prevent severe phlebitis, endothelial damage, and venous thrombosis.

Sodium Chloride Equivalent ($E$-Value) Method

The $E$-value represents the mass of sodium chloride (in grams) that produces the same osmotic effect as $1.0\text{ gram}$ of the drug:

$E = 17 \cdot \frac{L_{\text{iso}}}{\text{MW}}$

Where $L_{\text{iso}}$ is the isosmotic freezing point depression constant (typically $3.4$ for univalent-univalent electrolytes, $1.9$ for non-electrolytes) and $\text{MW}$ is the molecular weight.

To calculate required NaCl for isotonicity in volume $V$ (mL):

$\text{Total NaCl required} = 0.009 \times V$ $\text{NaCl contribution from drug} = \text{Mass of drug (g)} \times E$ $\text{NaCl to add} = (0.009 \times V) - [\text{Mass of drug} \times E]$

---

Sterilization and Depyrogenation Technologies

Sterilization destroys or eliminates all viable microorganisms (bacteria, fungi, bacterial endospores, and viruses) from a product.

---

Pyrogens, Bacterial Endotoxins, and Particulate Control

• Bacterial Endotoxins: Lipopolysaccharides (LPS) derived from the outer cell membrane of Gram-negative bacteria (e.g., E. coli, Pseudomonas). The hydrophobic Lipid A core mediates biological toxicity.
  • Properties: Highly water-soluble, non-volatile, thermostable (survives standard autoclaving at $121^\circ\text{C}$), and passes freely through $0.22\ \mu\text{m}$ sterilizing filters.
  • Clinical Reaction: Triggers macrophage activation, interleukin-1 (IL-1) and TNF-$\alpha$ release, producing high fevers, systemic vasodilation, disseminated intravascular coagulation (DIC), and irreversible septic shock.
  • Testing: The Limulus Amebocyte Lysate (LAL) assay (utilizing an aqueous extract of horseshoe crab amebocytes) undergoes enzymatic gel-clotting or chromogenic color change in the presence of endotoxin.
  • Endotoxin Limits ($K/M$): For non-intrathecal parenterals, $K = 5.0\text{ EU/kg/hr}$; for intrathecal injectables, the limit is strictly $K = 0.2\text{ EU/kg/hr}$.
• Particulate Matter Standards: Parenterals must meet USP standards for sub-visible particles ($\ge 10\ \mu\text{m}$ and $\ge 25\ \mu\text{m}$) via light obscuration tests. Ampoules must always be withdrawn using a $5\text{-micron filter needle}$ to eliminate glass particulates before injection.

---

Biopharmaceuticals and Advanced Drug Delivery Systems

Biologics (monoclonal antibodies, recombinant cytokines, therapeutic enzymes) are large, complex macromolecules whose biological activity depends on intricate tertiary and quaternary protein structures.

Protein Degradation Pathways

• Physical Instability:
  • Denaturation: Unfolding of native 3D conformation into disordered polypeptide chains.
  • Aggregation: Self-association of unfolded monomers into sub-visible and visible aggregates. Aggregated proteins are highly immunogenic and can induce neutralizing anti-drug antibodies (ADAs).
  • Adsorption: Hydrophobic surface binding to glass vials or IV infusion tubing (e.g., insulin adhering to PVC lines). Formulations incorporate non-ionic surfactants (Polysorbate 20 or Polysorbate 80) to saturate interfaces and prevent adsorption.
• Chemical Instability: Deamidation of asparagine/glutamine residues, oxidation of methionine/cysteine residues, peptide bond hydrolysis, and disulfide scrambling.

Lyophilization (Freeze-Drying) Science

Lyophilization removes water by sublimation, stabilizing moisture-sensitive proteins for extended storage:

1. Freezing: Solution is frozen below its eutectic point or glass transition temperature ($T_g'$).
2. Primary Drying (Sublimation): Ice sublimates directly to vapor under high vacuum ($0.05-0.2\text{ mbar}$) below the formulation collapse temperature ($T_c$).
3. Secondary Drying (Desorption): Temperature is elevated to desorb residual bound water to $< 2%$ moisture.

• Cryoprotectants & Lyoprotectants: Non-reducing disaccharides (sucrose, trehalose) replace water hydrogen bonds at the protein surface ("water replacement hypothesis") and vitrify into a protective amorphous glass matrix that prevents conformational collapse.
• Bulking Agents: Mannitol or glycine provide structural elegance and mechanical stability to the lyophilized cake.

Advanced Nanocarriers and Targeted Delivery

• Liposomes: Spherical vesicles composed of synthetic phospholipid bilayers enclosing an aqueous core. Pegylated (stealth) liposomes (e.g., liposomal doxorubicin / Doxil) evade clearance by the reticuloendothelial system (RES), prolonging circulation half-life from minutes to $\sim 55\text{ hours}$ and accumulating in tumor tissue via the Enhanced Permeability and Retention (EPR) effect, while markedly reducing cardiotoxicity.
• Lipid Nanoparticles (LNPs): Complex four-component lipid assemblies containing ionizable cationic lipids (to bind negatively charged mRNA and facilitate endosomal escape), helper phospholipids, cholesterol, and PEGylated lipids (used in mRNA COVID-19 vaccines).
• Antibody-Drug Conjugates (ADCs): A targeted monoclonal antibody linked covalently via a stable linker to a potent antineoplastic payload (e.g., trastuzumab emtansine / T-DM1), selectively delivering cytotoxic agents directly to antigen-expressing tumor cells.